Alfuzosin Hydrochloride
Product Images NDC 70934-306

9 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 70934-306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

70934 306 30 Master Bottle Label Approval Rev A 03 19

70934 306 30 Master Bottle Label Approval Rev A 03 19
Label for Alfuzosin Hydrochloride Extended-Release Tablets, 10 mg, containing 30 tablets. The label includes the NDC 70934-306-30, storage instructions to keep at 20°-25°C with permitted excursions, and cautions to protect from light and moisture. It also states Rx Only and advises to keep out of reach of children. The label shows Denton Pharma, Inc. DBA Northwind Pharmaceuticals as the manufacturer or labeler.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of alfuzosin hydrochloride, illustrating the arrangement of its atoms and bonds including methoxy groups, amine groups, and a hydrochloride salt moiety.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing alfuzosin plasma concentration (ng/mL) over 24 hours under fed and fasted conditions. Alfuzosin concentration increases more steeply and peaks higher in the fed state, while the fasted state shows lower and more stable concentrations over time. Time (hours) is on the x-axis, plasma concentration on the y-axis.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph depicting the mean change from baseline in IPSS total symptom score over 84 days of treatment. It compares placebo and alfuzosin hydrochloride extended-release tablets, showing greater symptom score reduction with alfuzosin. Statistical significance is indicated at p < 0.001.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph illustrating mean change from baseline in IPSS Total Symptom Score over 84 days of treatment comparing Alfuzosin hydrochloride extended-release tablets (N=137) and placebo (N=152). The graph shows greater symptom score reduction with Alfuzosin compared to placebo, with statistical significance at day 84 (p < 0.01).*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing the mean change from baseline in IPSS total symptom score over 84 days of treatment comparing placebo (N=150) and Alfuzosin hydrochloride extended-release tablets (N=151). The graph demonstrates a greater decrease in symptom score for the Alfuzosin group versus placebo, with statistically significant results (p < 0.01) by day 84.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
Line graph depicting mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment comparing placebo and Alfuzosin hydrochloride extended-release tablets. The Alfuzosin group shows a significant increase in mean change sustained over time, with statistical significance noted at day 84 (p < 0.001).*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A line graph showing the mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment. The graph compares placebo (N=147) and Alfuzosin hydrochloride extended-release tablets (N=136). The Alfuzosin group shows a higher increase in flow rate compared to placebo, with significant difference indicated at day 84 (p<0.05).*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over days of treatment (0, 14, 28, 56, 84) comparing placebo (N=150) and Alfuzosin hydrochloride extended-release tablets (N=151). The Alfuzosin group shows a higher increase in mean urine flow rate than placebo throughout the treatment period, with no statistically significant difference at day 84 (NS p > 0.05).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.